The global CD55 Antibody market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.

CD55 (decay-accelerating factor, DAF) is a GPI-anchored membrane glycoprotein that protects autologous cells from classical and alternative pathway of complement cascade.

United States market for CD55 Antibody is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for CD55 Antibody is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for CD55 Antibody is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key CD55 Antibody players cover:

• Merck
• Thermo Fisher Scientific
• Proteintech Group
• Aviva Systems Biology
• LifeSpan BioSciences

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CD55 Antibody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity.

Segmentation by Type

• Monoclonal
• Polyclonal

Segmentation by Application

• Immunochemistry (IHC)
• Immunofluorescence (IF)
• Immunoprecipitation (IP)
• Western Blot (WB)
• ELISA
• Others

Market by Region

• Americas
• APAC
• Europe
• Middle East & Africa

Companies coverage includes:

• Merck
• Thermo Fisher Scientific
• Proteintech Group
• Aviva Systems Biology
• LifeSpan BioSciences

Key Questions Addressed in this Report